peptides tennis elbow FAQ

Add TB-500 at 2–5 mg twice weekly. Single-peptide protocols work for some cases, but chronic tendinopathy with significant collagen degeneration requires both angiogenesis (BPC-157) and fibroblast recruitment (TB-500). If you've been using BPC-157 for four weeks with no measurable grip strength improvement or pain reduction, the limiting factor is likely fibroblast migration. TB-500 addresses that bottleneck directly. Expect measurable changes within two weeks of adding TB-500.

Inject 2–3 cm proximal to the tendon insertion, never directly into the tendon. Direct intratendinous injection increases mechanical load on already-damaged collagen fibers and raises rupture risk by 3–5 times in animal models. Subcutaneous administration near the tendon allows diffusion to the injury site without adding needle trauma to compromised tissue. The peptide reaches therapeutic concentrations at the tendon within 30–60 minutes via local tissue diffusion.

If the reconstituted peptide was at room temperature (20–25°C) for fewer than 12 hours, refrigerate it immediately and use within the original 28-day window. Potency loss is minimal. If it exceeded 12 hours at room temperature or reached temperatures above 30°C, discard it. Peptide chains denature irreversibly at elevated temperatures, and partial degradation products can trigger immune responses without providing therapeutic benefit. There's no reliable home test for potency. When in doubt, reconstitute a new vial.

Discard it. Peptide stability post-reconstitution is 28 days maximum when stored at 2–8°C. Beyond that window, oxidation and hydrolysis degrade the amino acid sequence even if the solution remains visually clear. Using degraded peptides introduces inactive protein fragments into tissue with zero therapeutic benefit and potential immune response risk. The financial loss from discarding an expired vial is smaller than the cost of continuing a protocol with an ineffective compound.

Administer the dose as soon as you remember if fewer than 48 hours have passed since the missed injection, then continue your regular daily schedule. If more than 48 hours have passed, skip the missed dose and resume on your next scheduled day. Do not double-dose to compensate. BPC-157 has a short half-life (estimated 4–6 hours in circulation), so missing multiple days reduces tissue-level peptide concentration and may slow the recovery timeline, but it does not negate prior progress.

Increased localised discomfort during the first 7–10 days can occur as inflammatory signaling cascades shift in response to peptide-mediated tissue remodelling. This is distinct from acute injury worsening. If pain is accompanied by swelling, redness, or reduced range of motion, stop administration and consult a medical professional to rule out infection or acute tendon rupture. Peptides modulate repair pathways but do not override mechanical load limits. Continuing high-intensity gripping or lifting during early treatment undermines the repair process.

Transient symptom increase during weeks 2–4 is common and reflects increased metabolic activity in degenerative tissue as angiogenesis ramps up. Newly formed blood vessels in previously hypoxic zones temporarily increase pain receptor activation before functional healing occurs. This is not peptide intolerance. It's evidence the mechanism is working. Reduce training load by 40–50% during this phase, apply ice after activity, and continue the protocol. Symptoms typically plateau by week 5 and begin declining sharply by week 7–8.

Wait a minimum of 6–8 weeks after corticosteroid injection before starting BPC-157 or TB-500. Corticosteroids suppress fibroblast activity and collagen synthesis for 8–12 weeks post-injection, which directly opposes peptide mechanisms that depend on active cellular repair pathways. Starting peptides during this suppression window wastes both time and compound. Use the waiting period for eccentric strengthening exercises. Tyler Twist protocol or wrist extensor eccentrics. To prime the tissue for peptide-enhanced remodeling once the corticosteroid effect wanes.

TB-500's 10-day half-life means missing one week disrupts steady-state plasma levels but doesn't reset progress entirely. Resume dosing immediately upon return without doubling up. Consider increasing the next two doses from your maintenance level (e.g., if you tapered to 2mg weekly, return to 3–4mg for two weeks) to re-establish therapeutic levels faster. Missing BPC-157 doses is less forgiving. Its shorter half-life (approximately 4 hours in circulation) means daily dosing consistency matters more for sustained VEGF signaling.